This review summarizes the cellular and molecular underpinnings of autoimmune demyelinating optic... more This review summarizes the cellular and molecular underpinnings of autoimmune demyelinating optic neuritis (ADON), a common sequela of multiple sclerosis and other demyelinating diseases. We further present nutritional interventions tested for people with multiple sclerosis focusing on strategies that have shown efficacy or associations with disease course and clinical outcomes. We then close by discuss the potential dietary guidance for preventing and/or ameliorating ADON.
Wegener's granulomatosis and Goodpasture's syndrome represent two major causes of... more Wegener's granulomatosis and Goodpasture's syndrome represent two major causes of a pulmonary-renal syndrome. We describe the clinical course and morphologic features of a patient in whom pulmonary manifestations of Wegener's granulomatosis developed and were followed six months later by anti-glomerular basement membrane disease. Although we regard this as a unique and probably fortuitous association, a genetic predisposition or a secondary form of anti-GBM disease cannot be excluded.
INTRODUCTIONAlzheimer's disease (AD) and AD‐related dementias (ADRD) are leading causes of de... more INTRODUCTIONAlzheimer's disease (AD) and AD‐related dementias (ADRD) are leading causes of death among older adults in the United States. Efforts to understand risk factors for prevention are needed.METHODSParticipants (n = 146,166) enrolled in the Women's Health Initiative without AD at baseline were included. Diabetes status was ascertained from self‐reported questionnaires and deaths attributed to AD/ADRD from hospital, autopsy, and death records. Competing risk regression models were used to estimate the cause‐specific hazard ratios (HRs) and 95% confidence intervals (CIs) for the prospective association of type 2 diabetes mellitus (T2DM) with AD/ADRD and non‐AD/ADRD mortality.RESULTSThere were 29,393 treated T2DM cases and 8628 AD/ADRD deaths during 21.6 (14.0–23.5) median (IQR) years of follow‐up. Fully adjusted HRs (95% CIs) of the association with T2DM were 2.94 (2.76–3.12) for AD/ADRD and 2.65 (2.60–2.71) for the competing risk of non‐AD/ADRD mortality.DISCUSSIONT2D...
ObjectiveTo identify components of a modified Paleolithic diet which may be related to patient ou... more ObjectiveTo identify components of a modified Paleolithic diet which may be related to patient outcomes in individuals with chronic-progressive multiple sclerosis (MS). Outcomes evaluated were fati...
Objective: To investigate associations between lipid profiles and fatigue in a cohort of progress... more Objective: To investigate associations between lipid profiles and fatigue in a cohort of progressive multiple sclerosis (MS) patients on a modified Paleolithic diet-based multimodal intervention. Background: Fatigue is a frequent and debilitating MS symptom that affects between 52%–93% of MS patients. Pharmacological options for treating MS-associated fatigue are limited. Dietary interventions have shown particular promise for treating MS-associated fatigue. Design/Methods: This study included 18 progressive MS patients who participated in a prospective longitudinal study of fatigue following a modified Paleolithic diet-based multimodal intervention that included neuromuscular stimulation and stress reduction. Fatigue was measured on the Fatigue Severity Scale (FSS) at baseline and every 3 months for 12 months. A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triglycerides (TG) was obtained on fasting blood samples at baseline and 12 months. Results: The FSS score decreased from a mean of 5.51 ± 1.31 at baseline to 3.03 ± 1.6 at 12-months. The modified Paleolithic-diet based multimodal intervention was associated with increases in HDL-C (p = 0.049) and with decreases in BMI (p 2 FSS points. Conclusions: Lipid profile variables are associated with the improvements in fatigue in progressive MS patients on a modified Paleolithic diet-based multimodal intervention. Study Supported by: This work was funded by Direct-MS. In-kind support was also provided from DJO Inc., Pinnaclife Inc., TZ Press LLC, and the Iowa City Veterans Administration Healthcare System, Iowa City, IA. Disclosure: Dr. Ramanathan has nothing to disclose. Dr. Fellows has nothing to disclose. Dr. Wahls holds stock and/or stock options in Dr. Terry Wahls LLC, TZ Press LLC, RDT LLC, The Wahls Institute, PLC, and the website www.terrywahls.com. Dr. Browne has nothing to disclose. Dr. Bisht has nothing to disclose. Dr. Snetselaar has nothing to disclose. Dr. Weinstock-Guttman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bianca Weinstock- Guttman received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis and Acorda. Dr. Weinstock-Guttman has received research support from Dr Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis, Acorda.
This review summarizes the cellular and molecular underpinnings of autoimmune demyelinating optic... more This review summarizes the cellular and molecular underpinnings of autoimmune demyelinating optic neuritis (ADON), a common sequela of multiple sclerosis and other demyelinating diseases. We further present nutritional interventions tested for people with multiple sclerosis focusing on strategies that have shown efficacy or associations with disease course and clinical outcomes. We then close by discuss the potential dietary guidance for preventing and/or ameliorating ADON.
Wegener's granulomatosis and Goodpasture's syndrome represent two major causes of... more Wegener's granulomatosis and Goodpasture's syndrome represent two major causes of a pulmonary-renal syndrome. We describe the clinical course and morphologic features of a patient in whom pulmonary manifestations of Wegener's granulomatosis developed and were followed six months later by anti-glomerular basement membrane disease. Although we regard this as a unique and probably fortuitous association, a genetic predisposition or a secondary form of anti-GBM disease cannot be excluded.
INTRODUCTIONAlzheimer's disease (AD) and AD‐related dementias (ADRD) are leading causes of de... more INTRODUCTIONAlzheimer's disease (AD) and AD‐related dementias (ADRD) are leading causes of death among older adults in the United States. Efforts to understand risk factors for prevention are needed.METHODSParticipants (n = 146,166) enrolled in the Women's Health Initiative without AD at baseline were included. Diabetes status was ascertained from self‐reported questionnaires and deaths attributed to AD/ADRD from hospital, autopsy, and death records. Competing risk regression models were used to estimate the cause‐specific hazard ratios (HRs) and 95% confidence intervals (CIs) for the prospective association of type 2 diabetes mellitus (T2DM) with AD/ADRD and non‐AD/ADRD mortality.RESULTSThere were 29,393 treated T2DM cases and 8628 AD/ADRD deaths during 21.6 (14.0–23.5) median (IQR) years of follow‐up. Fully adjusted HRs (95% CIs) of the association with T2DM were 2.94 (2.76–3.12) for AD/ADRD and 2.65 (2.60–2.71) for the competing risk of non‐AD/ADRD mortality.DISCUSSIONT2D...
ObjectiveTo identify components of a modified Paleolithic diet which may be related to patient ou... more ObjectiveTo identify components of a modified Paleolithic diet which may be related to patient outcomes in individuals with chronic-progressive multiple sclerosis (MS). Outcomes evaluated were fati...
Objective: To investigate associations between lipid profiles and fatigue in a cohort of progress... more Objective: To investigate associations between lipid profiles and fatigue in a cohort of progressive multiple sclerosis (MS) patients on a modified Paleolithic diet-based multimodal intervention. Background: Fatigue is a frequent and debilitating MS symptom that affects between 52%–93% of MS patients. Pharmacological options for treating MS-associated fatigue are limited. Dietary interventions have shown particular promise for treating MS-associated fatigue. Design/Methods: This study included 18 progressive MS patients who participated in a prospective longitudinal study of fatigue following a modified Paleolithic diet-based multimodal intervention that included neuromuscular stimulation and stress reduction. Fatigue was measured on the Fatigue Severity Scale (FSS) at baseline and every 3 months for 12 months. A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triglycerides (TG) was obtained on fasting blood samples at baseline and 12 months. Results: The FSS score decreased from a mean of 5.51 ± 1.31 at baseline to 3.03 ± 1.6 at 12-months. The modified Paleolithic-diet based multimodal intervention was associated with increases in HDL-C (p = 0.049) and with decreases in BMI (p 2 FSS points. Conclusions: Lipid profile variables are associated with the improvements in fatigue in progressive MS patients on a modified Paleolithic diet-based multimodal intervention. Study Supported by: This work was funded by Direct-MS. In-kind support was also provided from DJO Inc., Pinnaclife Inc., TZ Press LLC, and the Iowa City Veterans Administration Healthcare System, Iowa City, IA. Disclosure: Dr. Ramanathan has nothing to disclose. Dr. Fellows has nothing to disclose. Dr. Wahls holds stock and/or stock options in Dr. Terry Wahls LLC, TZ Press LLC, RDT LLC, The Wahls Institute, PLC, and the website www.terrywahls.com. Dr. Browne has nothing to disclose. Dr. Bisht has nothing to disclose. Dr. Snetselaar has nothing to disclose. Dr. Weinstock-Guttman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bianca Weinstock- Guttman received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis and Acorda. Dr. Weinstock-Guttman has received research support from Dr Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis, Acorda.
Uploads
Papers by Terry Wahls